SS Innovations International Inc. (NASDAQ: SSII) has demonstrated the ability to perform robotic-assisted cardiac surgery at a distance of approximately 7,500 miles, a showcase that underscores the growing potential of remote robotic surgery to extend specialist expertise beyond major medical centers. The company reported that its Chairman and CEO, Dr. Sudhir Srivastava, performed an atrial septal defect procedure on a patient in Bengaluru, India, while attending the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona. The procedure utilized the company’s SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console. The demonstration was part of a series of remote operations conducted during October medical conferences in Spain and India, including four additional robotic telesurgeries broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric and gynecological procedures.
The significance of these demonstrations lies in their implications for healthcare delivery. Remote robotic surgery could enable patients in underserved or remote locations to receive specialized surgical care from expert surgeons located anywhere in the world, potentially reducing travel burdens and improving access to timely interventions. As of October 23, 2026, the company reported 205 telesurgeries performed with the SSi Mantra system, including cardiac procedures, indicating progress in accumulating clinical experience. However, widespread adoption of telesurgery depends on several factors, including clinical validation, reliable connectivity, and regulatory requirements. SS Innovations is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027, though the timeline remains subject to the FDA’s review.
For investors, the announcements highlight the company’s efforts to position its technology at the intersection of robotics and telemedicine. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII. The demonstrations were featured in a press release disseminated by InvestorWire, a communications platform within the Dynamic Brand Portfolio at IBN. InvestorWire provides services such as editorial syndication to 5,000+ outlets and social media distribution, which help companies like SS Innovations reach a broad audience of investors and media.
The long-distance cardiac procedure represents a notable milestone in the field of robotic telesurgery, but its broader impact will hinge on rigorous clinical studies and regulatory approvals. If cleared by the FDA, the SSi Mantra could become part of a new class of surgical tools that allow hospitals to leverage specialized expertise across geographies, potentially transforming surgical care delivery. For now, the company’s demonstrations offer a glimpse of a future where distance is less of a barrier to accessing high-quality surgical care.
